The Important Contribution of Glucuronide Metabolite Hydrolysis to Detection and Quantitation in Urine Drug Testing

Significance of the topic

Urine drug testing is widely used in clinical, forensic and emergency medicine. Phase II metabolism by UDP‑glucuronosyltransferases commonly converts drugs and Phase I metabolites into glucuronide conjugates that dominate urinary excretion for many therapeutic and psychoactive classes (opioids, benzodiazepines, cannabinoids, antidepressants, etc.). Analytical workflows that measure only unconjugated (free) analytes risk underestimating total exposure and producing clinically relevant false negatives. This study quantifies the real‑world impact of enzymatic β‑glucuronide hydrolysis on detection sensitivity and quantitative results in a large emergency‑department patient cohort.

Study objectives and overview

• Determine how recombinant β‑glucuronidase hydrolysis changes detection and quantitation for a broad panel of drugs and metabolites in clinical urine specimens.
• Characterize analyte‑ and drug‑class‑specific dependence on glucuronide cleavage for identification and concentration measurement.
• Use paired analyses (with and without hydrolysis) on real patient samples to assess clinical impact rather than relying solely on spiked matrices.
• Cohort: urine from 400 emergency department patients previously collected and ethically approved; focused analysis on 360 samples with positive findings.

Methodology

• Panel: 110 drugs and Phase I metabolites targeted; quantitative analysis performed for 104 analytes using the Threshold Accurate Calibration (TAC) approach and a separate isomer‑selective cannabinoid method.
• Sample handling: every urine sample analyzed in matched pairs — once after recombinant β‑glucuronidase hydrolysis (IMCSzyme RT blend of two engineered variants) and once without hydrolysis.
• Calibration and dynamic range: TAC methodology with matrix normalization and 10‑fold dilution into analyte‑negative urine when required to achieve analytical ranges.
• Data: for most analytes the study used an average of ~25 matched observations (range 3–249) to compute percent glucuronidation, detection rates and quantitative impact.

Used instrumentation

• UHPLC: Waters ACQUITY UPLC I‑Class PLUS with Flow‑Through Needle (FTN).
• Columns: ACQUITY UPLC BEH Phenyl (1.7 µm, 2.1 × 50 mm) for TAC method; Cortecs UPLC C18+ (1.6 µm, 2.1 × 50 mm) for cannabinoid isomer separations.
• MS: Waters Xevo TQD tandem quadrupole mass spectrometer; ESI ionization (positive mode for TAC; ± for cannabinoids), unit mass resolution, typical source/desolvation settings cited in the study.
• Reagent for hydrolysis: recombinant β‑glucuronidase (IMCSzyme RT) composed of two variants selected to maximize O‑ and N‑glucuronide coverage.

Main results and discussion

• Overall impact: Across 360 samples with positive results, hydrolysis produced 1,866 positive drug/metabolite findings covering 76 of the 110 panel analytes.
• Contribution of glucuronides: Hydrolysis accounted for greater than 50% of the measured response for 39 of 76 analytes; for 24 analytes the glucuronide form contributed >80% of signal (notably in cannabinoid, benzodiazepine, opioid and psychiatric drug classes).
• Detection sensitivity: When only free analyte was measured, detection rates decreased sharply as the proportion of free analyte fell. Analytes with >90% free form had detection >99% without hydrolysis. For 32 analytes with average free fraction <40%, detection rates fell precipitously; 10% of analytes had detection rates of 0–20% without hydrolysis.
• False negatives: 39 analytes showed false negatives when hydrolysis was omitted. Sixteen of these (≈41%) had false‑negative rates >50% without hydrolysis. Four analytes—cannabidiol, α‑hydroxy‑alprazolam, 11‑hydroxy‑THC and buprenorphine—were not detected at all (100% false negatives) without hydrolysis under the study conditions.
• Quantitative impact: Hydrolysis contributed >50% of measured concentration for 39 analytes. For 16 analytes concentrations measured without hydrolysis were reduced by >99%. The decline in median concentration without hydrolysis was linearly correlated with the percentage of analyte present as glucuronide (regression slope ~1.09, intercept ~–4.4), indicating predictable underestimation when glucuronides are not cleaved.
• Enzyme selection: Use of recombinant enzyme blend reduced variability and improved coverage of recalcitrant O‑ and N‑glucuronides relative to many traditional enzyme sources; nonetheless, hydrolysis efficiency remains analyte‑dependent.

Benefits and practical applications

• Increased diagnostic sensitivity: Including an optimized glucuronide hydrolysis step substantially increases detection rates for many commonly tested drugs and metabolites.
• Improved quantitation: Hydrolysis yields more accurate total analyte concentrations, important for clinical interpretation, therapeutic monitoring, forensic reporting and PK/exposure assessment.
• Reduced false negatives: Particularly critical in emergency medicine and forensic contexts where missed detections may change clinical management or medicolegal outcomes.
• Workflow compatibility: The study demonstrates integration of recombinant glucuronidase hydrolysis into high‑throughput UPLC‑MS/MS workflows (TAC and isomer‑selective cannabinoid methods) using contemporary instrumentation.

Future trends and potential applications

• Recombinant enzyme development: Continued engineering of β‑glucuronidase isoforms (including multi‑isozyme blends and site‑directed variants) will improve hydrolysis of recalcitrant N‑glucuronides and structurally diverse conjugates.
• Standardization and guidelines: Greater evidence from real‑world cohorts supports updates to laboratory practice guidelines recommending hydrolysis for selected panels or analytes with high glucuronide fraction.
• Method automation: Automated hydrolysis modules and standardized reagent formulations can increase reproducibility and throughput in clinical and forensic laboratories.
• Targeted vs. direct measurement: Advances in LC‑MS/MS sensitivity and reference standards may enable direct quantitation of glucuronide conjugates in routine assays, reducing reliance on hydrolysis for some analytes.
• Clinical interpretation tools: Integration of percent‑glucuronidation data into laboratory reports and decision support could refine interpretation of timing, substance use patterns and compliance assessments.

Conclusions

The study demonstrates that enzymatic glucuronide hydrolysis using a recombinant enzyme blend is a major determinant of both detection sensitivity and quantitative accuracy for many urine drug tests. In this emergency‑department cohort, hydrolysis converted a substantial fraction of otherwise missed or underestimated analyte results into clinically and forensically meaningful findings. Laboratories performing definitive urine drug testing should evaluate panel composition and the expected glucuronidation profiles of target analytes; for many analytes, incorporation of optimized hydrolysis or direct glucuronide analysis is essential to avoid false negatives and to report accurate concentrations.

Reference

1. D’Ovidio C, Locatelli M, Perrucci M et al. LC‑MS/MS Application in Pharmacotoxicological Field: Current State and New Applications. Molecules. 2023;28:2127–39.
2. Liston HL, Markowitz JS, DeVane CL. Drug Glucuronidation In Clinical Psychopharmacology. J Clin Psychopharmacol. 2001;21(5):500–515.
3. Johnson‑Davis K. Opiate & Benzodiazepine Confirmations: To Hydrolyze or Not to Hydrolyze is the Question. J Appl Lab Med. 2018;2:564–572.
4. Smith HS. Metabolism and Disposition of Prescription Opioids: a Review. Pain Physician. 2012;15(3 Suppl):ES133–ES150.
5. French D, Wu AH, Lynch KL. Hydrophilic interaction LC–MS/MS Analysis of Opioids in Urine: Significance of Glucuronide Metabolites. Bioanalysis. 2011;3(23):2603–2612.
6. Matsuo T, Ogawa T, Iwai M, et al. Optimization of Enzymatic Hydrolysis of Glucuronide Conjugates for Five Psychoactive Drugs in Postmortem Urine. Forensic Toxicol. 2024;42(2):181–190.
7. Dinga Y, Peng M, Zhang T. Quantification of Conjugated Metabolites After Hydrolysis with β‑glucuronidase and Sulfatase: A Review. J Chromatogr B. 2013;925:38–50.
8. Wakabayashi M, Fishman WH. Comparative Ability of β‑glucuronidase Preparations to Hydrolyze Steroid Glucosiduronic Acids. Biochim Biophys Acta. 1961;48:198–199.
9. Southworth MJ, et al. Morphine Glucuronide Hydrolysis: Superiority of β‑glucuronidase from Patella vulgata. Pharmacology. 1982;28:83–86.
10. Namera A, Saito T, Nagao M. Evaluation of Commercial Recombinant and Conventional β‑glucuronidases for O‑ and N‑glucuronide Hydrolysis in Urinary Drug Screening. Forensic Toxicol. 2025;43:356–364.
11. Lee LA, McGee AC, Sitasuwan P et al. Factors Compromising Glucuronidase Performance in Urine Drug Testing. J Anal Toxicol. 2022;46(6):689–696.
12. Cone EJ, Yousefnejad D, Darwin WD et al. Incomplete Recovery of Prescription Opioids in Urine Using Enzymatic Hydrolysis of Glucuronide Metabolites. Drug Metab Dispos. 2007;35(4):649–654.
13. Klette KL, McMillin GA, Koons TL et al. Comparison of Purified β‑glucuronidases in Patient Urine Samples Shows Variable Hydrolysis Efficiency. J Anal Toxicol. 2018;43(3):221–227.
14. Zhang X, Sitasuwan P, Horvath G et al. Increased Activity of β‑glucuronidase Variants Produced by Site‑Directed Mutagenesis. Enzyme Microb Technol. 2018;109:20–24.
15. Schlachter CR, McGee AC, Sitasuwan PN, et al. Glycosyl Hydrolase Family 2 β‑glucuronidase Variants with Increased Activity on Recalcitrant Substrates. Enzyme Microb Technol. 2021;145:109742.
16. Rosano TG, Islam SMT, Rumberger JM et al. Definitive urine drug testing in emergency medicine: Recreational and psychiatric drug findings. J Mass Spectrom Adv Clin Lab. 2025;37:16–27.
17. Rosano TG, Rumberger JM, Scholz KL et al. Novel Matrix Normalization Technique for Accurate LC‑ESI‑MS/MS Detection and Quantification of Drugs and their Metabolites. Current Protocols. 3, e644.
18. Rosano TG, Rumberger JM, Wood M. Matrix Normalization Techniques for Definitive Urine Drug Testing. J Anal Toxicol. 2021;45:901–912.
19. Rosano TG, Ohouo PY, Wood M. Screening and Quantification of 64 Drugs and Metabolites in Human Urine Using UPLC‑MS/MS with Threshold Accurate Calibration. J Anal Toxicol. 2017;41:536–546.
20. Rosano TG, Cooper J, Scholz KL, Wood M. Confirmation of Cannabinoids in Forensic Toxicology Casework by Isomer‑Selective UPLC‑MS/MS. J Anal Toxicol. 2023;47:709–718.
21. Rosano TG, Rumberge JM, Konetchy RM et al. Direct‑to‑definitive Urine Drug Testing Panel with Addition of Xylazine and 4‑hydroxy Xylazine Identification and Quantitation. Waters Application Brief. 2025.
22. Rosano TG, Cooper JA, Scholz KL et al. Cannabinoid Isomer Identification and Quantitation by UPLC‑MS/MS in Forensic Urine. Waters Application Brief. 2024.